In this episode of The Promise of Personalized Medicine, Perry sits down with Sarah Clancey Overton, Director of Revenue Cycle Management at Velsera.

They discuss how genetic profiling is transforming healthcare—enabling targeted treatments, improving prognostic tools, and even opening doors for disease prevention.

The conversation highlights the critical role of diagnostic testing in precision medicine, the increasing collaboration between pharmaceutical companies and labs, and the challenges in payer coverage that impact patient access.

It examines why not all doctors are ordering comprehensive genetic profiling, how diagnostics and therapies can be better aligned, and what changes are needed to ensure patients receive the right treatment at the right time.

Tune in as they discuss the future of medicine—where data-driven insights and tailored treatments have the power to redefine patient care.

—-------

Stay connected with our host, Perry Dimas, here on LinkedIn!